Association of CD14 gene −260C>T and −561C>T polymorphisms with cancer susceptibility: A meta‐analysis

Background Two polymorphisms, −260C>T (rs2569190) and −561C>T (rs5744455), in the CD14 gene have been implicated in susceptibility to cancer. However, the results remain inconclusive. The current meta‐analysis was carried out aiming to confirm the function of these two polymorphisms on the susceptibility of cancer. Methods We collected eligible studies from databases, including PubMed, EMBASE, CNKI, Wanfang, and VIP (Weipu). We used logistic regression calculation to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results After strict selection, 24 studies with 5854 cases and 10339 controls for −260C>T and seven studies with 1809 cases and 7289 controls for −561C>T were finally enlisted into our analysis reference material. Pool results revealed that neither −260C>T, nor −561C>T was found to have any association with overall cancer susceptibility. Nevertheless, when stratified by cancer type, we detected a decreased risk associated with other cancers in a heterozygous model (OR = 0.69, 95% CI = 0.51–0.93, p = 0.014) and a dominant model (OR = 0.70, 95% CI = 0.53–0.93, p = 0.012) for −561C>T. An increased risk was found in other cancers under an allele model (OR = 1.29, 95% CI = 1.03–1.62, p = 0.026), in laryngeal cancer under a dominant model (OR = 1.38, 95% CI = 1.11–1.71, p = 0.003) and for a score ≤ 9 under a recessive model (OR = 1.45, 95% CI = 1.09–1.91, p = 0.009) for −561C>T. Conclusions In the present study, we conclude that the CD14 –260C>T and −561C>T polymorphisms might not be associated with overall cancer risk. Further studies are encouraged to confirm this conclusion.